TY  - JOUR
AU  - Skrede, Silje
AU  - Gonzalez-Garcia, Ismael
AU  - Martins, Luis
AU  - Berge, Rolf Kristian
AU  - Nogueiras, Ruben
AU  - Tena-Sempere, Manuel
AU  - Mellgren, Gunnar
AU  - Steen, Vidar Martin
AU  - Lopez, Miguel
AU  - Fernø, Johan
PY  - 2017
DO  - 10.1093/ijnp/pyx073
UR  - http://hdl.handle.net/10668/11671
T2  - The international journal of neuropsychopharmacology
AB  - Olanzapine is an orexigenic antipsychotic drug associated with serious metabolic adverse effects in humans. Development of valid rodent models for antipsychotic-induced metabolic adverse effects is hampered by the fact that such effects occur in...
LA  - en
PB  - Oxford University Press
KW  - antipsychotics
KW  - energy expenditure
KW  - estradiol
KW  - weight gain
KW  - Animals
KW  - Antipsychotic Agents
KW  - Benzodiazepines
KW  - Body Weight
KW  - Eating
KW  - Energy Intake
KW  - Estradiol
KW  - Female
KW  - Gene Expression Regulation
KW  - Injections, Intraventricular
KW  - Lipids
KW  - Olanzapine
KW  - Ovariectomy
KW  - Ovary
KW  - Rats
KW  - Rats, Sprague-Dawley
KW  - Uncoupling Protein 1
KW  - Weight Gain
TI  - Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats.
TY  - research article
VL  - 20
ER  -